AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Galectin Therapeutics Secures $10 Million Credit Line, Advances Belapectin Program With FDA Feedback.
ByAinvest
Monday, Dec 22, 2025 2:57 am ET1min read
Galectin Therapeutics has received written feedback from the FDA on its Belapectin program for MASH cirrhosis and portal hypertension. The FDA has aligned with Galectin on the patient population for a registration trial and plans to extend a follow-up Type C meeting to finalize trial design elements and present new biomarker data. Galectin has also secured a $10 million credit line to fund expenditures through at least March 2027.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet